SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

ALEXANDRIA, MN - January 24, 2026 - PRESSADVANTAGE - Individuals living with or at risk for glaucoma in the region can ...

The authors noted that this is the first prospective case series to apply a structured, protocol-based approach to ...

A study published in Cureus showed that omidenepag isopropyl achieved significant and sustained reductions in intraocular ...

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

Doctors warn that unsupervised steroid use is a rising cause of secondary glaucoma, emphasizing the need for awareness and ...

Bengaluru: Doctors across India have raised serious concerns over the growing and often unsupervised use of steroid ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

“With acute glaucoma, the symptoms are usually quite obvious and include pain/aching/discomfort in the eye and blurred vision ...

The ophthalmic devices market is experiencing robust growth, propelled by several converging factors that shape demand and ...

Patient awareness of glaucoma differs markedly depending on urban and rural locations and the patient population, and that awareness or lack thereof impacts diagnosis, treatment, ...

Researchers have predicted that cases of glaucoma, a common eye condition that can lead to blindness if not treated, are ...